key: cord-0850528-58nhygwk
authors: Matsuoka, Ayaka; Koami, Hiroyuki; Shinada, Kota; Sasaki, Akira; Yamazaki, Hirotaka; Mori, Kosuke; Nakayama, Kento; Asahi, Miho; Yoshitake, Kunimasa; Narumi, Shogo; Koba, Mayuko; Kawaguchi, Atsushi; Sakamoto, Yuichiro
title: Investigation of predictors of bleeding complications in COVID‐19 using rotational thromboelastometry (ROTEM(Ⓡ)): A retrospective study
date: 2022-05-23
journal: Health Sci Rep
DOI: 10.1002/hsr2.655
sha: a81e9e8e8a49ef3f20ab891876a73cd2ed5de9e7
doc_id: 850528
cord_uid: 58nhygwk

BACKGROUND: Hemorrhagic complications in patients with coronavirus 19 disease (COVID‐19) are infrequent but associated with a prognosis. This study aimed to elucidate the risk factors for bleeding complications in patients with COVID‐19 using rotational thromboelastometry (ROTEM) parameters and blood tests performed at admission. METHODS: In total, 31 patients with severe COVID‐19 treated intensively at Saga University Hospital were included in this study. Patients were divided into two groups according to the presence or absence of hemorrhagic complications. Results from the blood tests performed at admission and during hospitalization, and ROTEM values acquired upon admission, were compared between the two groups. RESULTS: There were significant differences in ROTEM values upon admission between the bleeding and non‐bleeding groups. Receiver operating curve analysis showed that the area under the curve for prothrombin time international normalized ratio (PT‐INR) and extrinsically‐activated test with tissue factor (EXTEM) amplitude at 10 min (A10) were 0.82 (0.52–0.92) and 0.81 (0.58–0.93), respectively. Logistic regression analysis with PT‐INR and EXTEM A10 as factors calculated an odds ratio of 1.94 (1.04–3.62) and EXTEM A10 0.86 (0.71–1.05) for bleeding complications occurrence. CONCLUSION: ROTEM may be a sensitive predictor for bleeding complications in patients with COVID‐19.

Coronavirus disease 2019 (COVID- 19) is an infection caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which has rapidly spread worldwide after the outbreak in Wuhan, China, in December 2019. The COVID-19 pandemic has had a global, social, and economic impact. 1 COVID-19 causes acute respiratory distress syndrome by inducing a cytokine storm, which can lead to rapid respiratory deterioration and ultimately, death. 2 In addition, COVID-19 is known to induce coagulopathy by a mechanism different from sepsisinduced coagulopathy or disseminated intravascular coagulopathy. 3, 4 Infection with SARS-CoV-2 causes a marked elevation in fibrinogen, D-dimer, and fibrin/fibrinogen degradation products (FDP), leading to hypercoagulability throughout the body and a high incidence of thromboembolism. 5 Therefore, anticoagulants are often used in combination with other drugs to treat COVID-19, even though an increased risk of bleeding complications has been reported. 6 Although the frequency of bleeding complications in COVID-19

is not as high as that of thromboembolism, it can be a serious complication. 5 A retrospective study by Atschl et al. 7 found that bleeding events were more likely to occur in the COVID-19 death group than in the survival group and that bleeding events are a risk factor for death. Codagnone et al. 8 to predict blood coagulability. 9 The SLTs prothrombin time (PT) and activated partial thromboplastin time (APTT) reflect the response at a time when thrombin production is only 4% of the total amount. 10 PT and APTT may not accurately reflect coagulability in vivo because the plasma component is separated and does not reflect the activity of platelets. 11 POCT using whole blood has the potential to detect coagulopathies that are not detected using SLT coagulation tests. 12 Since 2013, ROTEM ® has been used at our hospital to diagnose patients in intensive care and monitor coagulopathies during hospitalization. This study examined the risk factors for bleeding complications in COVID-19 using the SLTs and ROTEM ® parameters.

This was a single-center, retrospective, observational study conducted at the intensive care unit (ICU) of the Saga University Hospital. This hospital is a facility that treats critically ill patients with COVID-19 from the Saga Prefecture who require respiratory support by tracheal intubation or high-flow nasal cannula (HFNC). Thirty-one patients with severe COVID-19 who were admitted to the hospital between April 1, 2021, and August 31, 2021, were included in the study. COVID-19 was diagnosed using SARS-CoV-2 RNA detection or antigen detection. Anticoagulation was performed according to the anticoagulation algorithm with unfractionated heparin developed and proposed by Sato et al. 13 for Japanese patients. This study was approved by the Ethics Committee of Saga University (2021-04-R-08).

All participants were given an opportunity to opt-out.

Basic patient information, medical history, life history, and blood test results were extracted from electronic medical records. The diagnosis of bleeding complications was based on the World Health Organization (WHO) grading system. 14 All patients were divided into two groups: a bleeding group and a group without bleeding complications (no bleeding group). Patients with grade 2 bleeding scores or higher were defined as those with bleeding complications (bleeding group).

First, blood test data were collected at admission. For the bleeding group, the highest or lowest value of each laboratory test up to the day of the bleeding event was extracted. For the nonbleeding group, the highest or lowest value of each laboratory test for the entire hospital stay was extracted. For analysis by ROTEM ® delta, extrinsically-activated test with tissue factor (EXTEM), internallyactivated test with tissue factor (INTEM), and fibrin-based EXTEM and the platelet inhibitor cytochalasin D (FIBTEM) 15 were measured in all patients. The timing of analysis was at ICU admission, the day after admission, and every other day thereafter. The acute physiology and chronic health evaluation II (APACHE II) score was calculated on the day of admission based on the acute physiologic assessment and chronic health evaluation second edition proposed by Kanus et al. 16 

All statistical analyses were performed using the JMP Pro version 14 software package (SAS Inc.). Continuous variables were described as the median and quartiles. Comparisons of each parameter were performed using Fisher's exact test and Wilcoxon rank-sum test.

Statistical significance was set at p < 0.05. The distribution of values for factors with a p < 0.01 was shown in box plots. Receiver operating characteristic (ROC) curve analysis was performed for the risk factors that showed statistically significant differences between the bleeding and nonbleeding groups at the univariate level.

Youden's index was used to determine the cutoff value, sensitivity, and specificity of each risk factor. Logistic regression analysis was performed using the factors identified as having a high area under the curves (AUCs) in this univariate analysis to search for independent risk factors for bleeding complications occurrence.

Bleeding prediction by these combined factors was also performed to obtain AUC, sensitivity, and specificity. 

The baseline characteristics of the 31 patients included in this study are shown in Table 1 . All patients admitted to our hospital required respiratory support with HFNC or oral tracheal intubation. The overall mortality rate was 25.8%, and the median length of hospital stay was 10 There was no significant difference in patient physical background between the bleeding and nonbleeding groups. With regard to comorbidities, patients in the bleeding group had significantly higher chronic obstructive pulmonary disease and APACHE II scores compared to patients in the nonbleeding group (Table 2 ).

There were no significant differences in mortality or hospital stay between the bleeding and nonbleeding groups. There was a significant difference in the PT test international normalized ratio (Table 3) .

PT-INR and EXTEM A10 values differed significantly between the bleeding and nonbleeding groups (p < 0.01), as shown in Figure 1 . Expanding on these results, predictions using a combination of factors were considered. In this study, the bleeding group was small (n = 9), so the analysis was limited; however, for reference, we devised a 

COVID-19 and coagulation: bleeding and thrombotic manifestations of SARS-CoV-2 infection

Clinical features of patients infected with 2019 novel coronavirus in Wuhan

Pathological findings in rotation thromboelastometry associated with thromboembolic events in COVID-19 patients

Thromboembolic complications in critically ill COVID-19 patients are associated with impaired fibrinolysis

The impact of COVID-19 disease on platelets and coagulation

Comprehensive landscape of heparin therapy for COVID-19

Hemorrhagic presentations of COVID-19: risk factors for mortality

Restarting "normal" life after Covid-19 and the lockdown: evidence from Spain, the United Kingdom, and Italy

TEG and ROTEM: Technology and clinical applications

The dynamics of thrombin formation

Rapid thrombelastography (r-TEG) identifies hypercoagulability and predicts thromboembolic events in surgical patients

Utility of thromboelastography and/or thromboelastometry in adults with sepsis: A systematic review

A new challenge of unfractionated heparin anticoagulation treatment for moderate to severe COVID-19 in Japan

Measuring clinical bleeding using a standardized daily report form and a computer algorithm for adjudication of WHO bleeding grades

A systematic review on the rotational thrombelastometry (ROTEM ® ) values for the diagnosis of coagulopathy, prediction and guidance of blood transfusion and prediction of mortality in trauma patients

Apache II: a severity of disease classification system

Severe arterial thrombosis associated with Covid-19 infection

Thrombocytopenia and thrombosis in hospitalized patients with COVID-19

Thrombosis and coagulopathy in COVID-19

COVID-19 and thrombosis: from bench to bedside

Evaluation of coagulation function by rotation thromboelastometry in critically ill patients with severe COVID-19 pneumonia

Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy

Clinical characteristics of coronavirus disease 2019 in China

COVID-19 associated coagulopathy: thrombosis, hemorrhage and mortality rates with an escalated-dose thromboprophylaxis strategy

Rotational thromboelastometry (ROTEM) profiling of COVID-19 patients

Racial differences in human platelet PAR4 reactivity reflect expression of PCTP and miR-376c

The authors would like to thank all staff of the Saga University Hospital (Saga City, Japan) for their involvement in the treatment of COVID-19 patients.

The authors declare no conflicts of interest.

Data are available on request from the authors.

We ensured that the manuscript was an honest, accurate, and transparent account of the reported study, that no important aspects of the study were omitted, and that there were no discrepancies with the planned study.